Aurora Cannabis, the Canada-based medical cannabis company, announced an investment over five years into operational upgrades at its EU-GMP manufacturing facility in Leuna, Germany.
The company said the improvements will increase flower growth capacity, product quality and drive cost efficiency.
"This investment marks a significant milestone in our commitment to operational excellence and long-term growth in Europe," said Alex Miller, Executive Vice President of Operations, Science and Supply Chain at Aurora. "These upgrades will strengthen our supply chain resilience, expand our domestic capabilities in EU-GMP certified manufacturing, and position us to best meet the growing demand for high-quality medical cannabis in Europe with precision and efficiency."
As one of only three licensed cultivation facilities in the country, Aurora Leuna plays a role in supplying locally grown medical cannabis to meet the needs of Germany's patient base. Aurora Leuna currently grows cultivars under the IndiMed brand, and this expansion will enable the site to grow additional cultivars available from Aurora's genetics library.
